Drugs / Etamsylate
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT02604719 | Nov 2015 → May 2016 | — | Ahmed Alanwar | Unknown | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT07442513 | Dec 2025 → Oct 2027 expected | disease related to hematopoietic stem cell transplant, thrombocytopenia | First Affiliated Hospital of Zhejiang University | Recruiting | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT06190535 | Jan → Dec 2024 | pancreas disorder | University of Sfax | Unknown | No outcome recorded |
Also used as a comparator or background therapy in 3 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT04656067 Comparator | Apr → Oct 2020 | — | Egymedicalpedia | Completed | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT05806307 Comparator | Mar → Oct 2023 | drug pseudoallergy, uterine corpus leiomyoma | Cairo University | Unknown | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT05273632 Comparator | Mar → Sep 2022 | — | Egymedicalpedia | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Etamsylate | “Tranexamic acid and Etamsylate are slowly given intravenously 10 minutes before start of Cesarean Delivery” NCT05273632 ↗ |
| Known as | Dicynone | “Arm in which etamsylate (Dicynone injectable 250mg/2ml) is administrated through the nasogastric tube (NT) 2 ampules twice (X2)/day for 48 hours.” NCT06190535 ↗1“and 500 mg ethamsylate (2 ampoule of ethamsylate 250 mg, Dicynone, OM pharma, Geneva, Switzerland)” NCT05806307 ↗ |
| Known as | Ethamsylate | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05806307 ↗ |
| Action | Inhibit | “It also inhibits synthesis and action of prostaglandins causing platelet disaggregation, vasodilation and increased capillary permeability.” NCT06190535 ↗ |
| Route | Intravenous | “intravenous administration” NCT02604719 ↗ |